Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grail Inc (GRAL)

Grail Inc (GRAL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,075,011
  • Shares Outstanding, K 38,982
  • Annual Sales, $ 147,170 K
  • Annual Income, $ -408,350 K
  • EBIT $ -410 M
  • EBITDA $ 808 M
  • 60-Month Beta 4.52
  • Price/Sales 14.10
  • Price/Cash Flow 2.01
  • Price/Book 0.94

Options Overview Details

View History
  • Implied Volatility 84.11% (+3.50%)
  • Historical Volatility 227.09%
  • IV Percentile 17%
  • IV Rank 28.13%
  • IV High 127.59% on 04/21/25
  • IV Low 67.09% on 09/04/25
  • Expected Move (DTE 20) 7.57 (14.21%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 1,573
  • Volume Avg (30-Day) 2,812
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 30,787
  • Open Int (30-Day) 26,848
  • Expected Range 45.67 to 60.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -2.92
  • Number of Estimates 1
  • High Estimate -2.92
  • Low Estimate -2.92
  • Prior Year -3.10
  • Growth Rate Est. (year over year) +5.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.50 +28.27%
on 02/23/26
109.35 -51.32%
on 02/03/26
-55.75 (-51.16%)
since 01/27/26
3-Month
41.50 +28.27%
on 02/23/26
118.84 -55.21%
on 01/22/26
-56.93 (-51.68%)
since 11/26/25
52-Week
20.44 +160.42%
on 04/07/25
118.84 -55.21%
on 01/22/26
+13.94 (+35.50%)
since 02/27/25

Most Recent Stories

More News
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

MENLO PARK, Calif. , Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...

GRAL : 53.23 (-8.38%)
Lost Money on GRAIL, Inc. (GRAL)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential...

GRAL : 53.23 (-8.38%)
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO , Feb. 24, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc....

GRAL : 53.23 (-8.38%)
Stocks Settle Higher as SCOTUS Rejects President Trump’s Tariffs

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.69%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.87%. March E-mini...

GOOGL : 311.76 (+1.42%)
AMAT : 372.30 (-0.91%)
ARES : 112.01 (-5.14%)
AAPL : 264.18 (-3.21%)
ADI : 355.79 (+0.41%)
AKAM : 98.39 (-1.51%)
MDB : 328.47 (-2.42%)
RNG : 36.45 (-1.86%)
$IUXX : 24,960.04 (-0.30%)
ZNM26 : 113-260s (+0.40%)
MSFT : 392.74 (-2.24%)
TSLA : 402.51 (-1.49%)
Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip?

Grail stock crashed on Friday after its NHS-Galleri clinical trial failed to meet primary endpoint. Here’s why investors are cautioned against treating GRAL shares as a bargain.

GRAL : 53.23 (-8.38%)
Stocks Rebound as Supreme Court Strikes Down President Trump’s Tariffs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.58%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.03%. March E-mini S&P futures (ESH26...

MSTR : 129.50 (-2.92%)
GOOGL : 311.76 (+1.42%)
AMAT : 372.30 (-0.91%)
ARES : 112.01 (-5.14%)
AAPL : 264.18 (-3.21%)
AVGO : 319.55 (-0.67%)
ADI : 355.79 (+0.41%)
GLXY : 20.59 (-6.15%)
AKAM : 98.39 (-1.51%)
RNG : 36.45 (-1.86%)
$IUXX : 24,960.04 (-0.30%)
COIN : 175.85 (-2.88%)
Stocks Rally After Supreme Court Rejects President Trumps Tariffs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. U.S. equities climbed on Friday...

APO : 104.60 (-8.57%)
ARES : 112.01 (-5.14%)
GH : 93.90 (-4.15%)
OWL : 10.55 (-5.97%)
$SPX : 6,878.88 (-0.43%)
AKAM : 98.39 (-1.51%)
LYV : 162.14 (+2.68%)
TPG : 43.42 (-3.45%)
RNG : 36.45 (-1.86%)
$IUXX : 24,960.04 (-0.30%)
ZNM26 : 113-260s (+0.40%)
QQQ : 607.29 (-0.32%)
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail’s executive officers and whether investor losses may be...

GRAL : 53.23 (-8.38%)
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8  Million

GRAL : 53.23 (-8.38%)
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time

GRAL : 53.23 (-8.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.

See More

Key Turning Points

3rd Resistance Point 60.19
2nd Resistance Point 58.53
1st Resistance Point 55.88
Last Price 53.23
1st Support Level 51.57
2nd Support Level 49.91
3rd Support Level 47.26

See More

52-Week High 118.84
Fibonacci 61.8% 81.25
Fibonacci 50% 69.64
Fibonacci 38.2% 58.03
Last Price 53.23
52-Week Low 20.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar